Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight and raises the price target from $4 to $6.
Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight and raises the price target from $4 to $6.